Pharmaceutical and biotechnology company Laurus Labs reported decent performance in the second quarter of 2022-23 with a 30.9% y-o-y revenue growth. This was supported by robust growth in synthesis and non-ARV (anti-retroviral) API segments. However, the price erosion in the ARV segment and elevated operational costs dragged net profit, which grew 15.6% y-o-y. Laurus Labs offers a diverse product portfolio that includes generic FDF (finished